One Shot Cures Not Good for "Cash Flow" | This Goldman Sach's report examines the drivers behind gene therapy, genetically-engineered cell therapy and gene editing.  Goldman sees a $5 trillion market for genone medicine.  The report also makes interesting & disturbing comments on the potential for "one short" cures vs the more financially lucrative chronic therapies (search "one shor" in the document).

The potential to deliver "one shot cures" is one of the most attractive aspects of gene therapy...However, such treatments offer a very different outlook with regard to recurring revenue versus chronic could represent a challenge for...sustained cash flow.

Read Entire Report

Last modified onMonday, 18 October 2021 11:45
Dagny Taggart

Dagny Taggart is Vice-President in Charge of Operations for Taggart Transcontinental.  Dagny is responsible for all the workings of the railroad.

Login to post comments